BCM
BIB icon

Blume Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Blume Capital Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-600
Closed -$31K – 294
2014
Q3 		$31K Hold
600
– – 0.02% 119
2014
Q2 		$28K Sell
600
-600
-50% -$23.7K 0.02% 127
2014
Q1 		$48K Buy
+1,200
New +$54.5K 0.04% 106

Other funds holding BIB

AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ABI
Adamant Biomedical Investments Zurich, Switzerland $418M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Blume Capital Management's BIB Position: Q4 2014 in Review

Blume Capital Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2014, closing a stake of 600 shares — an estimated $31K sold.

Blume Capital Management first reported a position in BIB in Q1 2014 and held it in 3 quarters. The position peaked at $48K in Q1 2014. 29 funds tracked by Wall St. Rank hold BIB as of Q4 2014.

  • Blume Capital Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Blume Capital Management sold 600 ProShares Ultra NASDAQ Biotechnology shares in Q4 2014, an estimated $31K.
  • Blume Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2014 and held it in 3 quarters.
  • Blume Capital Management's ProShares Ultra NASDAQ Biotechnology position peaked at $48K in Q1 2014.
  • 29 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2014.

Based on Blume Capital Management's 13F filing for Q4 2014, filed 10 Feb 2015.